KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
2009 · British Journal of Cancer · 557 citations
https://doi.org/10.1038/sj.bjc.6605177
C
Chiara Cremolini
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
967
Papers
20.5K
Citations
65
h-index
241
i10-index
Chiara Cremolini is an academic researcher. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Genetic factors in colorectal cancer & Gastric Cancer Management and Outcomes. The author has an h-index of 65, co-authored 822 publications.
ORCID: 0000-0002-0520-4841Papers by this author
worksQuantitative evidence for early metastatic seeding in colorectal cancer
2019 · Nature Genetics · 508 citations
https://doi.org/10.1038/s41588-019-0423-x
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
2023 · New England Journal of Medicine · 392 citations
https://doi.org/10.1056/nejmoa2214963
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
2020 · British Journal of Cancer · 315 citations
https://doi.org/10.1038/s41416-020-0894-7
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
2023 · The Lancet · 279 citations
https://doi.org/10.1016/s0140-6736(23)00772-9
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
2023 · The Lancet Oncology · 227 citations
https://doi.org/10.1016/s1470-2045(23)00150-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat